Repligen’s Neuro Research Attracts Major Grant Funding

Massachusetts-based biopharma company, Repligen, has received over $6 million in grant funding to advance its HDAC inhibitor research program. HDACs are therapeutic targets being actively pursued in drug discovery efforts for ALS and other neurodegenerative diseases.

Click here to read more.

Share this: